G2 Risk Solutions Finalizes EverC Transaction
G2 Risk Solutions (G2RS) today announced the completion of its transaction with EverC, expanding G2RS’ global reach and adding proven AI-powered risk solutions to its product suite.
Now with the acquired capabilities of EverC, G2RS delivers a comprehensive suite of AI- and analyst-driven risk solutions. Products are built to help global banks, merchant acquirers and online marketplaces strengthen defenses against fraud, scams and illegal or unsafe transactions. This includes the recently launched Smart Scan, an AI-powered risk assessment tool for marketplaces and their payment providers.
Other solutions from G2RS include proprietary risk intelligence, merchant onboarding, continuous monitoring, education and professional services, scam detection solutions and automated risk management.
“Adding EverC's deep marketplace expertise and battle-tested AI to our portfolio promises to fortify online marketplaces against escalating threats, strengthening what has become the circulatory system of global e-commerce,” said Rochelle Blease, president of G2RS.
“Together as a single organization, we’ll leverage proven AI and unrivaled expertise to raise the industry standard for e-commerce risk innovation,” said Brian Longe, chief executive officer of G2RS, who added that G2RS now serves nearly every major payment provider worldwide from offices in the U.S., Europe, India and Israel.
The mission-focused companies have agreed not to publicly disclose financial terms of the deal.
The transaction has been supported by several advisors, including DLA Piper LLP, which is acting as legal advisor to G2RS; PJT, acting as financial advisor to G2RS; Deutsche Bank, acting as financial advisor to EverC; and Meitar, acting as legal advisor to EverC.
About G2 Risk Solutions (G2RS)
G2 Risk Solutions is the definitive expert in risk and compliance business intelligence for financial institutions and online platforms. We are industry pioneers providing market-leading solutions for merchant risk, identity verification, digital commerce risk, bankruptcy risk, and credit risk and regulatory reporting. We are driving innovation and shaping the future of risk management through unprecedented data, technology, and global compliance and risk expertise, providing the financial services and digital commerce ecosystems with the tools needed to navigate complex and ever-changing regulatory requirements and mitigate risk. To learn more, visit g2risksolutions.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251006378196/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TCG Crossover (“TCGX”) Announces Oversubscribed $1.3B TCGX Fund III6.10.2025 14:00:00 CEST | Press release
TCG Crossover (“TCGX”) today announced the successful closing of its third fund, TCGX Fund III, with $1.3 billion in capital commitments. Fund III attracted support from both current TCGX investors and new institutional investors, foundations, pensions, and endowments. With the close of Fund III, TCGX has now raised more than $3.1 billion in total capital since its founding in 2021. TCGX Fund III exceeded its initial target, underscoring strong global investor demand. The fundraise marks a significant milestone and is an endorsement of the differentiated strategy and TCGX’s fully flexible mandate to invest across both private and public markets. “Exceeding our target for Fund III highlights the deep trust and conviction our investors have placed in our team and approach,” said Dr. Chen Yu, Founder and Managing Partner of TCGX. “We remain steadfast in our mission to back visionary entrepreneurs and companies advancing disruptive medicines to improve patient outcomes.” “We are grateful t
CareDx Announces New IVD Products and IVDR Certification for AlloSeq® Tx and QTYPE®at the 2025 American Society of Histocompatibility & Immunogenetics Annual Meeting6.10.2025 13:05:00 CEST | Press release
Furthers Global Leadership in Donor Organ and Transplant Recipient HLA Typing CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced new innovations and products that will be featured at The American Society for Histocompatibility and Immunogenetics (ASHI) 2025 Annual Meeting, held October 6th to 10th in Orlando, Florida. The company also announced that its AlloSeq® Tx and QTYPE® products have received certification for compliance to the In Vitro Diagnostic Regulation (IVDR) in the European Union. “This week at ASHI 2025, we will highlight our continued investment in creating life changing solutions that allow transplant patients to thrive,” said John Hanna, President and Chief Executive Officer. “The new product innovations and regulatory milestone underscore CareDx’s co
INVESTMENT FORUM - Senegal Is Betting on Forum Invest in Senegal 2025 (Fii 2025) to Accelerate the Inflow of Foreign Capital6.10.2025 11:59:00 CEST | Press release
In 2024, the country attracted nearly $3 billion in FDI, primarily in energy and infrastructure, according to official data As the landscape of foreign direct investment (FDI) flows into Africa is being reshaped, Senegal aims to capture a growing share of this capital through the Forum Invest in Senegal 2025 (Fii Senegal 2025) (http://apo-opa.co/3KzxBkp), which opens on Tuesday in Diamniadio. “Senegal is positioning itself as a crossroads between Africa and the rest of the world, a gateway for attracting capital, technology, and expertise,” explains Bakary Séga Bathily, Director General of APIX, the agency responsible for investment promotion and major infrastructure projects. With the central theme of ‘connecting opportunities, building the future,’ the event—held under the patronage of His Excellency, President Bassirou Diomaye Diakhar Faye—aims to showcase a portfolio of strategic projects across three key sectors: Energy: The development of natural gas from Yakaar-Teranga, combined
Bimiralisib, Topical PI3K/mTOR Inhibitor Shows Up To 92% Clearance Rate And Superior Tolerability In Proof-Of-Concept Actinic Keratosis Study6.10.2025 11:43:00 CEST | Press release
Torqur AG Announced Full Phase 2 Results at EADV Congress 2025 Torqur AG, subsidiary of Swiss Rockets incubator and a clinical-stage company advancing targeted therapies in oncodermatology and oncology, announced the results of the full Phase 2 proof-of-concept study results of topical bimiralisib gel (2%) for the treatment of actinic keratosis (AK) at the European Academy of Dermatology and Venereology (EADV) Congress 2025 in Paris, the largest dermatology conference in Europe. The randomized, multi-center study evaluated topical bimiralisib gel as a field-directed treatment for AK on the face, scalp, and/or back of hands. Results demonstrated substantial efficacy and a favorable safety profile, supporting further clinical development: Efficacy: 92% ofcomplete or near complete response withOlsen grade 1 patients, and overall, 52% of patients in the 2-week period and 71% in the 4-week period achieved an Investigator’s Global Assessment (IGA) score of 0–1 (complete or partial clearance)
Celltrion Presents Positive Real-World Data on Switching from intravenous (IV) to subcutaneous (SC) infliximab at UEG Week 2025 Meet the Expert sessions6.10.2025 11:00:00 CEST | Press release
Switching from intravenous (IV) to subcutaneous (SC) infliximab was shown to be well tolerated, with a low relapse risk for most IBD patients and high treatment persistence1, 2 Celltrion, Inc. today showcased real-world evidence supporting the use of subcutaneous (SC) infliximab, confirming the efficacy and safety of switching to SC infliximab 120mg every two weeks in patients with inflammatory bowel disease (IBD). The real-world evidence was presented at the Meet the Expert (MTE) Sessions at UEG 2025, and included presentations from Professor Nicolas Mathieu, Medical Director of MICI Institut Privé, Cliniques des Cèdres and Associate Professor of Gastroenterology, and Prof Anthony Buisson, Head of IBD Unit at University Hospital Estaing, Clermont Ferrand, France. Professor Nicolas Mathieu presented a real-life study which demonstrated that the switch from IV infliximab to SC infliximab is well tolerated amongst patients. The presentation particularly highlighted the results from the m
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom